Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Jenner

Showing results (1-10 of 177) with videos related to

Pageof 18
Sort By:
Handbook of Clinical Neurology|September 24, 2008
Oxidative stress and Parkinson's diseasePeter Jenner
Neurology|December 10, 2003
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PDPeter Jenner
Neurology|July 21, 2005
A novel dopamine agonist for the transdermal treatment of Parkinson's diseasePeter Jenner
Neurology|March 23, 2002
Pharmacology of dopamine agonists in the treatment of Parkinson's diseasePeter Jenner
Annals of Neurology|January 8, 2009
Functional models of Parkinson's disease: a valuable tool in the development of novel therapiesPeter Jenner
Current Opinion in Neurology|June 8, 2004
Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's diseasePeter Jenner
Neurology|October 13, 2004
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's diseasePeter Jenner
International Review of Neurobiology|September 2, 2014
An overview of adenosine A2A receptor antagonists in Parkinson's diseasePeter Jenner
Parkinsonism & Related Disorders|February 4, 2010
From the MPTP-treated primate to the treatment of motor complications in Parkinson's diseasePeter Jenner
Movement Disorders : Official Journal of the Movement Disorder Society|November 29, 2018
The treatment of levodopa-induced dyskinesias: Surfing the serotoninergic wavePeter Jenner
Pageof 18

Showing results (1-10 of 177) with videos related to

Sort By:
Pageof 18
Handbook of Clinical Neurology|September 24, 2008
Oxidative stress and Parkinson's diseasePeter Jenner
Neurology|December 10, 2003
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PDPeter Jenner
Neurology|July 21, 2005
A novel dopamine agonist for the transdermal treatment of Parkinson's diseasePeter Jenner
Neurology|March 23, 2002
Pharmacology of dopamine agonists in the treatment of Parkinson's diseasePeter Jenner
Annals of Neurology|January 8, 2009
Functional models of Parkinson's disease: a valuable tool in the development of novel therapiesPeter Jenner
Current Opinion in Neurology|June 8, 2004
Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's diseasePeter Jenner
Neurology|October 13, 2004
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's diseasePeter Jenner
International Review of Neurobiology|September 2, 2014
An overview of adenosine A2A receptor antagonists in Parkinson's diseasePeter Jenner
Parkinsonism & Related Disorders|February 4, 2010
From the MPTP-treated primate to the treatment of motor complications in Parkinson's diseasePeter Jenner
Movement Disorders : Official Journal of the Movement Disorder Society|November 29, 2018
The treatment of levodopa-induced dyskinesias: Surfing the serotoninergic wavePeter Jenner
Pageof 18